nct_id,brief_title,official_title,overall_status,start_date,completion_date,last_update,study_type,phase,enrollment,enrollment_type,allocation,intervention_model,primary_purpose,masking,condition,intervention_name,intervention_type,primary_outcome_count,secondary_outcome_count,min_age,max_age,sex,healthy_volunteers,lead_sponsor_name,lead_sponsor_class,collaborator_count,location_count,countries
NCT02137239,Regimen Optimization Study,"Evaluation of Acute Rejection Rates in de Novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (Belatacept)-Based Immunosuppression",COMPLETED,2015-12-31,2019-05-02,2021-06-22,INTERVENTIONAL,PHASE2,58.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Kidney Transplantation,Thymoglobulin|Belatacept|mycophenolate mofetil(MMF)|Corticosteroids|Everolimus(EVL)|Tacrolimus(TAC),DRUG,1,27,18 Years,75 Years,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,20,United States|Argentina
NCT04427072,Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation,"A Phase III, Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib Versus SoC Docetaxel Chemotherapy in Previously Treated Patients With EGFR wt, ALK Negative, Locally Advanced or Metastatic (Stage IIIB/IIIC or IV) NSCLC Harboring MET Exon 14 Skipping Mutation (METΔex14).",TERMINATED,2020-09-25,2023-11-06,2025-05-16,INTERVENTIONAL,PHASE3,22.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Carcinoma, Non-Small-Cell Lung",Capmatinib|Docetaxel,DRUG,1,20,18 Years,100 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,43,Spain|Italy|Belgium|South Korea|Russia|France|Hungary|Lithuania|Thailand|Portugal|Germany|Netherlands|South Africa|Vietnam|Brazil|India|Malaysia|Bulgaria
NCT02593175,Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC,"Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy",COMPLETED,2016-11-03,2025-04-03,2025-11-06,INTERVENTIONAL,PHASE2,43.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Stage I Breast Cancer AJCC v7|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Triple-Negative Breast Carcinoma,Carboplatin|Paclitaxel|Panitumumab,DRUG|BIOLOGICAL,1,0,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,0,1,United States
NCT03019575,Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043),"A Phase III, Multi-Center, Open Label, Single-Group Trial to Investigate the Efficacy and Safety of MK-8962 (Corifollitropin Alfa) in Combination With Human Chorionic Gonadotropin (hCG) for Initiation or Restoration of Puberty as Assessed by Increased Testicular Volume in Adolescent Males 14 to <18 Years Old With Hypogonadotropic Hypogonadism (MK-8962-043)",COMPLETED,2017-02-02,2020-05-05,2024-05-23,INTERVENTIONAL,PHASE3,17.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hypogonadotropic Hypogonadism,Corifollitropin alfa|hCG,DRUG,4,13,14 Years,17 Years,MALE,False,Organon and Co,INDUSTRY,0,15,Denmark|Italy|Russia|South Africa|Mexico|Brazil
NCT04779957,Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy,Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy ; a Pilot Phase II Study.,COMPLETED,2021-10-01,2024-08-09,2025-12-31,INTERVENTIONAL,PHASE2,18.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Kidney Transplantation|Graft Failure,Tocilizumab,DRUG,1,2,18 Years,,ALL,False,"University Hospital, Toulouse",OTHER,0,1,France
NCT02465801,Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein,Efficacy and Safety Phase II Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein for Injection to Prevent Neutrophilic Granulocytopenia Among Chemotherapy Patients,COMPLETED,2014-12-16,2016-04-26,2017-07-18,INTERVENTIONAL,PHASE2,216.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Chemotherapy-induced Neutropenia,HSA-GCSF 1.2 mg|HSA-GCSF 1.5 mg|GCSF,DRUG,1,5,18 Years,65 Years,FEMALE,False,Tianjin SinoBiotech Ltd.,INDUSTRY,0,1,China
NCT03802201,Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia,A Phase 2 Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) β-Thalassemia Subjects With Chronic Anemia,COMPLETED,2018-12-19,2020-07-31,2021-07-16,INTERVENTIONAL,PHASE2,63.0,ACTUAL,,SEQUENTIAL,TREATMENT,NONE,β-thalassemia|Ineffective Erythropoiesis|Chronic Anemia,PTG-300,DRUG,2,0,12 Years,65 Years,ALL,False,"Protagonist Therapeutics, Inc.",INDUSTRY,0,33,United States|Italy|United Kingdom|Tunisia|Lebanon|Thailand|Turkey (Türkiye)|Greece|Malaysia
NCT03401112,A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia),"A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia)",COMPLETED,2018-01-26,2020-08-28,2025-05-15,INTERVENTIONAL,PHASE2,100.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Sickle Cell Disease,IMR-687|Placebo,DRUG,1,6,18 Years,55 Years,ALL,False,"Cardurion Pharmaceuticals, Inc.",INDUSTRY,1,13,United States|United Kingdom
NCT01511081,Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT),"Randomized Phase II Study Comparing Stereotactic Body Radiotherapy (SBRT) With Stereotactic Body Proton Therapy (SBPT) for Centrally Located Stage I, Selected Stage II and Recurrent Non-Small Cell Lung Cancer",TERMINATED,2012-08,2016-10,2017-12-07,INTERVENTIONAL,PHASE2,21.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Non-small-cell Lung Cancer,SBRT (stereotactic body radiotherapy)|SBPT (stereotactic body proton therapy),RADIATION,1,1,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,2,1,United States
NCT04592419,"A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)","A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO)",COMPLETED,2020-09-25,2023-01-19,2024-06-26,INTERVENTIONAL,PHASE3,568.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Macular Edema|Retinal Vein Occlusion,KSI-301|Aflibercept|Sham Procedure,DRUG|OTHER,2,8,18 Years,,ALL,False,Kodiak Sciences Inc,INDUSTRY,0,141,Puerto Rico|United States|Italy|Spain|Slovakia|France|Hungary|Poland|Germany|Israel|Czechia|Latvia
NCT02353728,Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy,"Detection, Monitoring, and Molecular Characterization of Leukemic Stem Cells From Patients With Chronic Myeloid Leukemia (CML) Undergoing Therapy With Nilotinib",COMPLETED,2015-01,2021-02,2022-03-25,INTERVENTIONAL,PHASE2,16.0,ACTUAL,,SINGLE_GROUP,BASIC_SCIENCE,NONE,Chronic Myeloid Leukemia,Nilotinib,DRUG,1,0,18 Years,,ALL,False,Weill Medical College of Cornell University,OTHER,1,1,United States
NCT03513328,Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation,"PEDS024, Phase I/II Feasibility Study of Busulfan Fludarabine and Thiotepa Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) for Children With Non-Malignant Disorders",COMPLETED,2018-06-15,2023-02-19,2023-09-15,INTERVENTIONAL,PHASE1|PHASE2,6.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Bone Marrow Failure Syndrome|Thalassemia|Sickle Cell Disease|Diamond Blackfan Anemia|Acquired Neutropenia in Newborn|Acquired Anemia Hemolytic|Acquired Thrombocytopenia|Hemophagocytic Lymphohistiocytoses|Wiskott-Aldrich Syndrome|Chronic Granulomatous Disease|Common Variable Immunodeficiency|X-linked Lymphoproliferative Disease|Severe Combined Immunodeficiency|Hurler Syndrome|Mannosidosis|Adrenoleukodystrophy,Thiotepa--single daily dose|Thiotepa--escalated dose,DRUG,1,7,3 Months,39 Years,ALL,False,University of Florida,OTHER,1,1,United States
NCT02239692,A Trial Comparing the PICOPREP Tailored Dosing Schedule to the PICOPREP Day-before Dosing Schedule for Colon Cleansing in Preparation for Colonoscopy,"A Randomised, Assessor-blinded, Multi-centre Trial Comparing the Efficacy, Safety and Tolerability of the PICOPREP Tailored Dosing Schedule to the PICOPREP Day-before Dosing Schedule for Colon Cleansing in Preparation for Colonoscopy",COMPLETED,2014-11,2015-06,2016-06-23,INTERVENTIONAL,PHASE3,204.0,ACTUAL,RANDOMIZED,PARALLEL,,SINGLE,Bowel Cleansing,PICOPREP,DRUG,2,4,18 Years,,ALL,False,Ferring Pharmaceuticals,INDUSTRY,0,3,Germany|France|Netherlands
NCT03101111,Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area,Phase 2 Study of a Live Attenuated Measles Virus-Vectored Chikungunya Vaccine in a Previously Epidemic Area,COMPLETED,2017-08-09,2019-04-02,2021-07-19,INTERVENTIONAL,PHASE2,34.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Chikungunya,MV-CHIK|MMR-vaccine,BIOLOGICAL,1,1,21 Years,50 Years,ALL,True,Themis Bioscience GmbH,INDUSTRY,1,1,Puerto Rico
NCT04765371,"Comparison Between Prednisolone and Dexamethasone on Mortality in Patients on Oxygen Therapy, with CoViD-19","Comparison Between Prednisolone and Dexamethasone on D28 Mortality in Patients on Oxygen Therapy, with CoViD-19: Multicenter, Randomized, Open-label Non-inferiority Study",COMPLETED,2021-03-03,2022-02-10,2024-09-19,INTERVENTIONAL,PHASE3,89.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Coronavirus Infection,DEXAMETHASONE|PREDNISOLONE,DRUG,1,5,18 Years,,ALL,False,Hôpital NOVO,OTHER,0,8,France
NCT04756271,Safety and Immunogenicity of Oxford AstraZeneca Vaccine Against COVID-19 Infection,Safety and Immunogenicity of Oxford AstraZeneca Vaccine in Zagazig University Hospital Health-care Workers,COMPLETED,2021-02-11,2021-12-22,2022-02-09,INTERVENTIONAL,PHASE3,246.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Vaccine Adverse Reaction|Seroconversion,SARS-Cov-2 neutralizing antibody titer,BIOLOGICAL,2,0,18 Years,,ALL,True,Zagazig University,OTHER_GOV,0,1,Egypt
NCT01828034,"First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma","A Phase I/II Study of First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma",COMPLETED,2013-04,2019-05-30,2020-11-17,INTERVENTIONAL,PHASE1|PHASE2,42.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced Biliary Tract Carcinoma,Gemcitabine|Cisplatin|MEK162,DRUG,3,3,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,1,United States
NCT04618744,A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH),"A Double-Blind, Randomized, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)",COMPLETED,2020-11-24,2022-06-27,2024-08-07,INTERVENTIONAL,PHASE2,32.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2|NASH - Nonalcoholic Steatohepatitis",ORMD-0801 (Insulin) capsule 8 mg BD|Placebo,DRUG|OTHER,1,20,18 Years,70 Years,ALL,False,"Oramed, Ltd.",INDUSTRY,1,3,United States|Israel
NCT03031444,Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis,A Multicenter Study of Prognosis and the Efficacy Comparison of Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Patients(Clinical Risk Score≥3) of Resectable Colorectal Liver Metastasis,COMPLETED,2016-01,2020-12-30,2021-02-01,INTERVENTIONAL,PHASE2|PHASE3,135.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Colorectal Cancer Stage IV|Metastasis,Cetuximab plus FOLFIRI/FOLFOX|FOLFIRI/FOLFOX/CapeOX,DRUG,1,2,18 Years,80 Years,ALL,False,Peking University Cancer Hospital & Institute,OTHER,4,4,China
NCT03830164,"Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer","Pentoxifylline, Atorvastatin, and Vitamin E (PAVE) as Treatment for Radiation-Induced Erectile Dysfunction",COMPLETED,2019-11-20,2022-11-02,2023-10-17,INTERVENTIONAL,PHASE2,14.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Male Erectile Disorder|Prostate Adenocarcinoma|Erectile Dysfunction, CTCAE|Impotence",Atorvastatin|Pentoxifylline|Vitamin E Compound,DRUG|DIETARY_SUPPLEMENT,1,2,18 Years,,MALE,False,M.D. Anderson Cancer Center,OTHER,1,1,United States
NCT03970109,HLAB-002 of ANS-6637 for Alcohol Use Disorder,Human Laboratory Study of ANS-6637 for Alcohol Use Disorder,TERMINATED,2019-10-08,2020-05-22,2024-10-29,INTERVENTIONAL,PHASE2,43.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Alcohol Use Disorder,ANS-6637|Placebo oral tablet,DRUG,1,16,21 Years,,ALL,False,National Institute on Alcohol Abuse and Alcoholism (NIAAA),NIH,0,3,United States
NCT01276509,Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease,"A Double-blind, Randomized, Placebo-controlled, Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera)",COMPLETED,2011-04-06,2015-10-09,2021-06-03,INTERVENTIONAL,PHASE2,265.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Crohn's Disease,PF-00547659 SC injection|PF-00547659 SC injection|PF-00547659 SC injection|PF-00547659 SC injection,DRUG,1,12,18 Years,75 Years,ALL,False,Shire,INDUSTRY,0,137,Canada|United States|Japan|Belgium|Spain|Norway|South Korea|Slovakia|France|Poland|Austria|Germany|Netherlands|Serbia|South Africa|Bulgaria
NCT03199963,Trial of 4-Hydroxytamoxifen (4-OHT) Gel in Women Aimed at Reducing Dense Breast Tissue,"A Randomized, Double-blind, Placebo Controlled Trial of 4-Hydroxytamoxifen Gel for Reducing Breast Tissue Density in Women With BI-RADS Breast Density Categories C or D",TERMINATED,2017-08-21,2019-04-23,2022-07-26,INTERVENTIONAL,PHASE3,223.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Mammographic Breast Density,4-OH tamoxifen|Placebo,DRUG,1,6,35 Years,75 Years,FEMALE,False,"BHR Pharma, LLC",INDUSTRY,0,19,Germany|United States|Spain
NCT00737893,Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy,Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy: a Prospective Randomized Controlled Trial (ERECT),COMPLETED,2017-07-01,2019-12-31,2021-04-08,INTERVENTIONAL,PHASE2,56.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Prostate Cancer|Erectile Dysfunction,Placebo|Erythropoietin (EPO),DRUG,1,21,40 Years,65 Years,MALE,False,Johns Hopkins University,OTHER,0,1,United States
NCT05008393,Efficacy of PJS-539 for Adult Patients With COVID-19.,"Efficacy of PJS-539 for Adult Patients With SARS-CoV-2: Multicentre, Phase 2, Randomized, Double-blind, Placebo-controlled Clinical Trial.",COMPLETED,2021-09-25,2022-03-04,2022-04-12,INTERVENTIONAL,PHASE2,153.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Covid19|COVID-19 Pneumonia,PJS-539 Dose 1|PJS-539 Dose 2|Placebo,DRUG,1,6,18 Years,,ALL,False,Hospital do Coracao,OTHER,1,1,Brazil
NCT01762904,Residual Effect of Chlorhexidine-alcohol Compared to Triclosan-alcohol,Residual Effect of Chlorhexidine 2% / Isopropyl Alcohol 70% Compared to Triclosan 1% / Isopropyl Alcohol 70%,COMPLETED,2013-01,2013-10,2014-07-02,INTERVENTIONAL,PHASE3,135.0,ACTUAL,,SINGLE_GROUP,PREVENTION,SINGLE,Infectious Diseases,Bacterial culture of the prepared skin's areas with two antiseptics and two controls|Preparing skin's areas to be tested with two antiseptics and two controls,OTHER,3,1,18 Years,,ALL,True,Universidad de Guanajuato,OTHER,1,1,Mexico
NCT03136484,Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes,Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes,COMPLETED,2017-03-15,2018-11-16,2020-01-21,INTERVENTIONAL,PHASE3,788.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes|Diabetes Mellitus, Type 2",Semaglutide|Canagliflozin|Placebo (canagliflozin)|Placebo (semaglutide),DRUG,1,60,18 Years,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,119,Canada|United States|Italy|United Kingdom|Ireland|Argentina|Lebanon|Sweden|Mexico|India|Malaysia|Brazil
NCT04224584,A Mechanism Based Proof of Concept Study of the Effects of Duloxetine in the Treatment of Patients With Osteoarthritic Knee Pain,A Mechanism Based Proof of Concept Study of the Effects of Duloxetine in the Treatment of Patients With Osteoarthritic Knee Pain,COMPLETED,2020-01-01,2021-07-01,2022-02-16,INTERVENTIONAL,PHASE2,40.0,ACTUAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,TRIPLE,"Osteoarthritis, Knee",Duloxetine|Placebo oral tablet,DRUG,1,0,40 Years,75 Years,ALL,False,Kristian Kjær Petersen,OTHER,2,1,Denmark
NCT02542514,Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma,Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma,COMPLETED,2015-09,2021-12-01,2022-04-14,INTERVENTIONAL,PHASE2,52.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Primary Central Nervous Lymphoma|Intraocular Lymphoma,Ibrutinib,DRUG,1,7,18 Years,,ALL,False,The Lymphoma Academic Research Organisation,OTHER,0,10,France
NCT01839916,Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies,Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies,COMPLETED,2013-04-04,2018-08,2019-08-07,INTERVENTIONAL,PHASE2,77.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia,therapeutic allogeneic lymphocytes|laboratory biomarker analysis,OTHER|BIOLOGICAL,1,5,14 Years,75 Years,ALL,False,University of Chicago,OTHER,1,1,United States
NCT02379806,The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study,Prevention of Symptomatic Venous Thromboembolism by Low Molecular Weight Heparin in Hospitalized Medical Patients Aged 70 Years and Older : a Randomized Placebo-Controlled Study The SYMPTOMS (SYstematic Elderly Medical Patients Thromboprophylaxis : Efficacy on Symptomatic OutcoMeS) Study,COMPLETED,2015-09-03,2020-12-29,2022-07-05,INTERVENTIONAL,PHASE3,2560.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Venous Thromboembolism,Enoxaparin|Placebo,DRUG,1,1,70 Years,,ALL,False,"University Hospital, Brest",OTHER,0,46,Switzerland|France
NCT06022406,Fecal Microbiota Translantation (FMT) to Reduce Inflammation in PLWH: The Gutsy Pilot Study,Fecal Microbiota Transplantation to Reduce Immune Activation in ART-treated People Living With HIV With Low CD4/CD8 Ratio: The Gutsy Study,COMPLETED,2024-07-31,2025-08-13,2025-09-03,INTERVENTIONAL,PHASE2,20.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,HIV-1-infection,FMT capsules|Placebo capsules,BIOLOGICAL,1,17,18 Years,,ALL,False,Jean-Pierre Routy,OTHER,1,1,Canada
NCT02639533,Brain Response to Single Dose of Pregabalin in Fibromyalgia,"Pregabalin Acute Effects on Cortical Excitability, Psychophysical Parameters, and Serum Markers of Neuroplastic Processes in Fibromyalgia: a Placebo Controlled, Double Blinded, Randomized, Crossover Clinical Trial",COMPLETED,2014-12,2017-01,2018-02-08,INTERVENTIONAL,PHASE2|PHASE3,27.0,ACTUAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,QUADRUPLE,Fibromyalgia,Pregabalin|Placebo,DRUG|OTHER,2,7,18 Years,65 Years,FEMALE,True,Hospital de Clinicas de Porto Alegre,OTHER,3,0,
NCT02834052,Pembrolizumab + Poly-ICLC in MRP Colon Cancer,A Phase I/II Trial of Pembrolizumab (MK-3475) and Poly-ICLC in Patients With Metastatic Mismatch Repair-proficient (MRP) Colon Cancer,COMPLETED,2018-01-10,2022-07-29,2024-06-07,INTERVENTIONAL,PHASE1|PHASE2,42.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Metastatic Colon Cancer|Solid Tumor,pembrolizumab|Poly-ICLC,DRUG,3,3,18 Years,,ALL,False,Asha Nayak,OTHER,2,1,United States
NCT02931175,ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study),"An Open-label, Multi-center, Randomized, Phase II Study of the Safety,Efficacy and Bioactivity of Two Dose Regimens of Subcutaneous Injections of ACTH Gel in Patients With Non-infectious Uveitis",COMPLETED,2017-11-10,2021-10-28,2025-12-17,INTERVENTIONAL,PHASE2,28.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Uveitis,ACTH gel,DRUG,2,16,18 Years,,ALL,False,Quan Dong Nguyen,OTHER,1,7,United States
NCT02581657,"Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM","Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus",COMPLETED,2015-10,2016-11,2018-04-10,INTERVENTIONAL,PHASE2,37.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,PE0139 Injection|Placebo Injection,DRUG,1,14,18 Years,80 Years,ALL,False,PhaseBio Pharmaceuticals Inc.,INDUSTRY,0,6,United States
NCT04601857,Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma,A Phase 2 Study Evaluating Futibatinib (TAS 120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic Urothelial Carcinoma,TERMINATED,2021-01-07,2025-09-16,2025-12-31,INTERVENTIONAL,PHASE2,43.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Advanced and Metastatic Urothelial Cancer,Futibatinib|Pembrolizumab,DRUG,1,5,18 Years,,ALL,False,"Taiho Oncology, Inc.",INDUSTRY,1,18,Spain|United States|France
NCT05746481,Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases,A Phase II Clinical Trial of Tiragolumab in Combination With Atezolizumab in Patients With Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases.,TERMINATED,2023-08-10,2025-11-08,2026-01-22,INTERVENTIONAL,PHASE2,3.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non-small Cell Lung Cancer,Tiragolumab|Atezolizumab|Pemetrexed|Carboplatin,DRUG,1,10,18 Years,,ALL,False,"Liza Villaruz, MD",OTHER,1,1,United States
NCT01323400,Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST),"A Phase II Randomized Multicentre Study Evaluating the Efficacy of Pazopanib+Best Supportive Care (BSC) Versus BSC Alone in Metastatic and/or Locally Advanced Unresectable GIST, Resistant to Imatinib and Sunitinib",COMPLETED,2011-03,2016-02,2016-02-25,INTERVENTIONAL,PHASE2,81.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,GIST,Pazopanib|Best supportive care,DRUG|OTHER,1,8,18 Years,90 Years,ALL,False,Centre Leon Berard,OTHER,1,13,France
NCT02949700,Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma,A Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma,COMPLETED,2017-01-26,2022-07-07,2023-06-29,INTERVENTIONAL,PHASE1|PHASE2,26.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Head and Neck Squamous Cell Carcinoma,Metformin,DRUG,2,2,18 Years,,ALL,False,Baylor College of Medicine,OTHER,0,3,United States
NCT01994707,Remote Ischemic Preconditioning of Human Myocardium,Remote Ischemic Preconditioning of Human Myocardium,COMPLETED,2013-08,2016-04-27,2018-01-12,INTERVENTIONAL,PHASE2,134.0,ACTUAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,QUADRUPLE,Coronary Artery Bypass Graft Triple Vessel|Apoptotic DNA Damage,Remote ischemic preconditioning|Placebo,PROCEDURE,1,5,18 Years,80 Years,ALL,False,Medical University of Silesia,OTHER,1,1,Poland
NCT02592707,Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs,"An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)",TERMINATED,2017-03-06,2022-02-22,2023-07-19,INTERVENTIONAL,PHASE1|PHASE2,40.0,ACTUAL,,SEQUENTIAL,TREATMENT,NONE,Neuroendocrine Tumors,Satoreotide tetraxetan|Amino acid solution|Antiemetic,DRUG|OTHER,2,23,18 Years,,ALL,False,Ipsen,INDUSTRY,0,9,Canada|Denmark|United States|Australia|United Kingdom|France|Austria|Switzerland
NCT03108911,Gluten Free Diet in Diminishing Side Effects Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy,Gluten Free Diet for AML Patients Undergoing Induction Chemotherapy,TERMINATED,2017-07-27,2017-11-14,2017-11-17,INTERVENTIONAL,PHASE2,1.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,NONE,Acute Myeloid Leukemia,Best Practice|Biospecimen Collection|Dietary Intervention|Laboratory Biomarker Analysis,PROCEDURE|OTHER,3,0,18 Years,,ALL,False,"Rutgers, The State University of New Jersey",OTHER,1,1,United States
NCT03569371,A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa,"A Phase 2, Open-Label, Single-Arm Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa",COMPLETED,2018-07-17,2019-04-22,2022-09-26,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hidradenitis Suppurativa,INCB054707,DRUG,1,15,18 Years,75 Years,ALL,False,Incyte Corporation,INDUSTRY,0,4,United States
NCT02409264,The Effect of Individualised Homeopathic Treatment of Insomnia Disorder in Females,The Effect of Individualised Homeopathic Treatment of Insomnia Disorder in Females,COMPLETED,2015-01,2015-08,2016-05-17,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Insomnia Disorder,Individualised Homeopathic Remedy,OTHER,1,1,18 Years,45 Years,FEMALE,True,University of Johannesburg,OTHER,0,1,South Africa
NCT02131064,A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,"A Randomized, Multicenter, Open-Label, Two-Arm, Phase III Neoadjuvant Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Patients With HER2-Positive Breast Cancer",COMPLETED,2014-06-25,2018-05-29,2019-07-02,INTERVENTIONAL,PHASE3,444.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Neoplasms,Carboplatin|Docetaxel|Pertuzumab|Trastuzumab|Trastuzumab Emtansine,DRUG,1,21,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,79,Canada|United States|Spain|Belgium|Ukraine|South Korea|Russia|France|Taiwan|Germany
NCT04336332,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,TERMINATED,2020-04-01,2020-10-14,2023-02-28,INTERVENTIONAL,PHASE2,75.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,SARS-CoV-2|COVID-19,Hydroxychloroquine Sulfate + Azithromycin|Hydroxychloroquine Sulfate,DRUG|COMBINATION_PRODUCT,1,0,18 Years,,ALL,False,"Rutgers, The State University of New Jersey",OTHER,0,5,United States
NCT01309932,Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin,"A Phase 2B, Randomized Study to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda (BMS-914143) Administered With Ribavirin Plus a Single Direct Antiviral Agent (BMS-790052 or BMS-650032) Versus Pegasys Administered With Ribavirin (Part A) and of Pegylated Interferon Lambda (BMS-914143) Administered With or Without Ribavirin Plus 2 Direct Antiviral Agents (BMS-790052 and BMS-650032) (Part B) in Chronic Hepatitis C Genotype-1 Treatment naïve Subjects",COMPLETED,2011-03,2014-09,2015-10-09,INTERVENTIONAL,PHASE2,165.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hepatitis C,Pegylated Interferon Lambda (pegIFNλ)|BMS-790052 (NS5A Inhibitor)|Ribavirin (RBV)|BMS-650032 (NS3 Protease Inhibitor)|Pegylated Interferon Alfa-2a (pegIFNα-2a)|Pegylated Interferon Lambda (pegIFNλ)|Ribavirin (RBV)|Pegylated Interferon Lambda (pegIFNλ)|Ribavirin (RBV)|BMS-790052 (NS5A Inhibitor)|BMS-650032 (NS3 Protease Inhibitor)|Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)|Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)|Placebo for Ribavirin (RBV)|Placebo for Ribavirin (RBV),DRUG|BIOLOGICAL,3,14,18 Years,70 Years,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,40,Japan|United States|Australia|Italy|Puerto Rico|Spain|France|Germany|New Zealand
NCT04666298,Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C,"A Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Effect of Different Doses of Inclisiran Given as Subcutaneous Injections in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C",COMPLETED,2021-01-29,2022-10-19,2024-06-20,INTERVENTIONAL,PHASE2,312.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hypercholesterolemia|Heterozygous Familial Hypercholesterolemia,Inclisiran sodium|Placebo,DRUG,1,15,20 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,42,Japan
NCT02276898,A Randomized-Controlled Trial of Inhaled Hypertonic Saline (7%) to Evaluate the Lung Clearance Index,A Randomized-Controlled Trial of Inhaled Hypertonic Saline (7%) to Evaluate the Lung Clearance Index as a Short-term Pharmacodynamic Biomarker in Patients With Cystic Fibrosis.,COMPLETED,2011-11,2014-09,2015-05-22,INTERVENTIONAL,PHASE2,24.0,ESTIMATED,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Cystic Fibrosis,Hypertonic Saline 7%|Isotonic Saline 0.9% (Placebo),DRUG,1,3,6 Years,18 Years,ALL,False,The Hospital for Sick Children,OTHER,0,2,Canada
NCT01200498,Study of SB939 in Subjects With Myelofibrosis,"A Phase 2, Prospective, Open-Label Study to Determine the Safety and Efficacy of SB939, A Histone Deacetylase Inhibitor, in Subjects With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis (PMF; Post-Polycythemia Vera (PV) Myelofibrosis (MF), Or Post- Essential Thrombosis (ET) MF",COMPLETED,2010-11,2012-11,2014-01-30,INTERVENTIONAL,PHASE2,23.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Myeloproliferative Disorders,SB939,DRUG,1,0,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States
NCT03518398,Effectiveness and Safety of Intense Pulsed Light in Patients With Meibomian Gland Dysfunction,Effectiveness and Safety of Intense Pulsed Light in Patients With Meibomian Gland Dysfunction,COMPLETED,2018-07-03,2019-04-02,2019-06-19,INTERVENTIONAL,PHASE3,114.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Meibomian Gland Dysfunction (Disorder)|Dry Eye Syndromes,Intense Pulsed Light|Standard treatment,DEVICE|COMBINATION_PRODUCT,1,10,18 Years,80 Years,ALL,True,Chulalongkorn University,OTHER,0,1,Thailand
NCT01210898,Immunogenicity and Safety of V70P5 Revaccination Subjects,"A Phase IIIB, Observer-Blind, Randomized, Parallel Groups, Extension Study to Evaluate the Immunogenicity and Safety Following a Single Intramuscular Dose of a Sub-unit Adjuvanted or a Non-adjuvanted Influenza Vaccines in Healthy Children Previously Vaccinated in the V70P5 Study",COMPLETED,2010-09,2011-12,2016-12-01,INTERVENTIONAL,PHASE3,197.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Influenza,Adjuvanted seasonal influenza vaccine,BIOLOGICAL,4,2,18 Months,96 Months,ALL,True,Novartis Vaccines,INDUSTRY,0,16,Finland
NCT01821963,Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC),Telaprevir in Combination With Standard of Care in Hepatitis C Genotype 1 Infection in Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation,TERMINATED,2013-04,2014-02,2020-09-24,INTERVENTIONAL,PHASE3,1.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Infection,Pegylated Interferon Alfa 2a|Ribavirin|Telaprevir,DRUG,1,1,18 Years,69 Years,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States
NCT04261387,LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients,"A Two-Part (Open-Label Followed by Randomized, Double-Blind, Placebo-Controlled) Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of Topically Administered LUT014 for the Treatment of Radiation-Induced Dermatitis in Breast Cancer Patients",COMPLETED,2021-01-30,2022-07-15,2022-07-27,INTERVENTIONAL,PHASE1|PHASE2,28.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Radiation Dermatitis,LUT014 Gel|Placebo for LUT014 Gel,DRUG,2,4,18 Years,,FEMALE,False,Lutris Pharma Ltd.,INDUSTRY,0,2,United States
NCT01113593,A Study Characterizing Pharmacodynamic Profiles in Subjects With Chronic Obstructive Pulmonary Disease,"A Randomized, Multiple-Dose, Crossover Study Characterizing the Pharmacodynamic Profiles of Formoterol Fumarate Inhalation Solution and Formoterol Dry Powder Inhaler in Subjects With Stable Chronic Obstructive Pulmonary Disease",COMPLETED,2010-05,,2013-05-27,INTERVENTIONAL,PHASE2,45.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Chronic Obstructive Pulmonary Disease (COPD),Formoterol Fumarate|Formoterol Fumarate|Formoterol Fumarate|Foradil Aerolizer|Foradil Aerolizer,DRUG,1,0,40 Years,,ALL,False,Dey,INDUSTRY,0,4,United States
NCT03795116,Light Emitting Diode-Red Light (LED-RL) Phototherapy for Skin Scarring Prevention,Light Emitting Diode-Red Light (LED-RL) Phototherapy for Skin Scarring Prevention,COMPLETED,2019-03-18,2020-10-26,2022-06-01,INTERVENTIONAL,PHASE2,30.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Fibrosis|Skin Scarring|Skin Wound|Hypertrophic Scar|Scar|Keloid,LED-RL phototherapy|Mock irradiation,DEVICE,2,10,,,ALL,True,State University of New York - Downstate Medical Center,OTHER,0,1,United States
NCT03081416,"""THINK Trial: Treatment of Headache With IntraNasal Ketamine: A Randomized Controlled Trial Evaluating the Efficacy of Intranasal Ketamine Versus Standard Therapy in the Management of Primary Headache Syndromes in the Emergency Department""","""THINK Trial: Treatment of Headache With IntraNasal Ketamine: A Randomized Controlled Trial Evaluating the Efficacy of Intranasal Ketamine Versus Standard Therapy in the Management of Primary Headache Syndromes in the Emergency Department""",COMPLETED,2016-05,2017-10,2018-01-18,INTERVENTIONAL,PHASE3,80.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Headache|Intranasal Ketamine,Ketamine|Normal saline|Metoclopramide|Ketorolac|Dexamethasone|Benadryl,DRUG,1,6,18 Years,65 Years,ALL,True,Brooke Army Medical Center,FED,0,1,United States
NCT01652716,Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes,"A Randomized, Open-Label, Long-Term, Parallel-Group, Comparator-Controlled, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Exenatide Twice Daily in Subjects With Type 2 Diabetes Mellitus",COMPLETED,2013-01,2014-08,2018-07-03,INTERVENTIONAL,PHASE3,377.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",Exenatide once weekly suspension|Exenatide twice daily,DRUG,1,4,18 Years,,ALL,False,AstraZeneca,INDUSTRY,0,58,United States
NCT02394106,Ofatumumab in Children With Drug Resistant Idiopathic Nephrotic Syndrome,"Ofatumumab in Children With Steroid- and Calcineurin-inhibitor-resistant Nephrotic Syndrome: a Double-blind Randomized, Controlled, Superiority Trial",TERMINATED,2015-07,2019-06,2020-07-29,INTERVENTIONAL,PHASE2,13.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Nephrotic Syndrome,Ofatumumab|Placebo,DRUG|OTHER,1,3,2 Years,18 Years,ALL,False,Istituto Giannina Gaslini,OTHER,0,1,Italy
NCT06428084,Comparative Efficacy of Dexamethasone - Ondansetron Versus Dexamethasone - Haloperidol in Reducing PONV,Comparative Efficacy of Dexamethasone - Ondansetron Versus Dexamethasone - Haloperidol in Reducing Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy: A Randomized Controlled Trial,COMPLETED,2023-11-01,2024-02-28,2024-05-24,INTERVENTIONAL,PHASE2,38.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Laparoscopic Cholecystectomy,Ondansetron|Haloperidol,DRUG,1,0,18 Years,65 Years,ALL,False,Universitas Padjadjaran,OTHER,0,1,Indonesia
NCT01052077,Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of OPDC-34712 (1 to 3 mg/Day) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder.",COMPLETED,2010-03,2011-11,2015-11-02,INTERVENTIONAL,PHASE2,773.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Major Depressive Disorder,OPC-34712|Placebo|ADT,DRUG,1,9,18 Years,65 Years,ALL,False,"Otsuka Pharmaceutical Development & Commercialization, Inc.",INDUSTRY,0,43,United States
NCT01072175,"Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212","An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the BRAF Inhibitor GSK2118436 in Combination With the MEK Inhibitor GSK1120212 in Subjects With BRAF Mutant Metastatic Melanoma",COMPLETED,2010-03-26,2018-02-27,2019-07-05,INTERVENTIONAL,PHASE2,430.0,ACTUAL,NON_RANDOMIZED,,TREATMENT,NONE,Cancer,GSK2118436|GSK1120212,DRUG,30,27,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,15,United States|Australia
NCT01402401,Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients,"An Open-label, Single-arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AUY922 in Combination With Trastuzumab Standard Therapy as Second-line Treatment in Patients With HER2-positive Advanced Gastric Cancer",TERMINATED,2011-11,2013-06,2020-12-10,INTERVENTIONAL,PHASE2,21.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced Gastric Cancer,AUY922|Trastuzumab,DRUG,1,0,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,15,Japan|United States|Italy|Belgium|Spain|South Korea|France|Germany
NCT01189812,Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms,"A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Assess the Safety and Efficacy of Citalopram in Combination With Lithium or Placebo in the Treatment of Symptoms in Patients With Depressive Mood Disorders",COMPLETED,2010-03,2011-01,2011-08-24,INTERVENTIONAL,PHASE2,80.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Major Depressive Disorder|Dysthymia|Depression Not Otherwise Specified|Borderline Personality Disorder,Lithium Carbonate|Placebo|Citalopram,DRUG,1,2,18 Years,75 Years,ALL,False,Columbia Northwest Pharmaceuticals,INDUSTRY,0,2,United States
NCT01775930,Carfilzomib in Refractory Renal Cell Carcinoma (RCC),Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma,COMPLETED,2013-10,2019-01-18,2020-03-04,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Kidney Cancer,Carfilzomib,DRUG,1,4,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States
NCT03071965,Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel),Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel),COMPLETED,2017-05-12,2021-05-11,2025-05-09,INTERVENTIONAL,PHASE2,70.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,SINGLE,MacTel (Macular Telangiectasia) Type 2,Ciliary neurotrophic factor (CNTF)|Surgery|Surgery,PROCEDURE|BIOLOGICAL,2,4,21 Years,80 Years,ALL,False,Neurotech Pharmaceuticals,INDUSTRY,0,11,United States|Australia
NCT01621867,Repeated Application of Gene Therapy in CF Patients,"A Randomised, Double-blind, Placebo-controlled Phase 2B Clinical Trial of Repeated Application of Gene Therapy in Patients With Cystic Fibrosis",COMPLETED,2012-05,2014-05,2015-10-22,INTERVENTIONAL,PHASE2,130.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Cystic Fibrosis,pGM169/GL67A|Placebo,DRUG,1,3,12 Years,,ALL,False,Imperial College London,OTHER,3,3,United Kingdom
NCT01657292,Oleogel-S10 Versus Standard of Care in Healing of Grade 2a Burn Wounds,"Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Standard of Care in Accelerating the Healing of Grade 2a Partial-Thickness Burn Wounds",COMPLETED,2012-08,2014-07,2015-09-28,INTERVENTIONAL,PHASE3,61.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Burns,Oleogel-S10 ointment|Octenilin® wound gel,DRUG|DEVICE,1,10,18 Years,,ALL,False,Birken AG,INDUSTRY,0,9,Switzerland|Germany|Sweden|United Kingdom
NCT05397171,A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours,"A Phase I/IIa First-in-human, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours",TERMINATED,2022-06-07,2023-06-06,2024-10-01,INTERVENTIONAL,PHASE1|PHASE2,17.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,"Urinary Bladder Neoplasms|Colorectal Cancer|Carcinoma, Non-Small-Cell Lung",AZD8853|Zirconium-89 crefmirlimab berdoxam,DRUG,2,13,18 Years,130 Years,ALL,False,AstraZeneca,INDUSTRY,1,6,Canada|United States
NCT01628471,"MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer",A Phase I/IIa Dose-Escalation Study of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) Subjects,COMPLETED,2012-11,2015-09,2015-09-23,INTERVENTIONAL,PHASE1|PHASE2,20.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non Small Cell Lung Cancer,decitabine in combination with genistein,DRUG,1,2,18 Years,75 Years,ALL,False,Uman Pharma,INDUSTRY,3,1,Canada
NCT02874144,Anti-Inflammatory Agent in Sinusitis,"A Phase 2A, Single-Center, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy of an Anti-Inflammatory Agent in Patients With Sinusitis",COMPLETED,2016-06-20,2020-08-10,2022-05-25,INTERVENTIONAL,PHASE2,43.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Nasal Polyps,AZ compound|Collection of Biological Specimens|Intranasal corticosteroid|Placebo,DRUG|OTHER,3,2,18 Years,70 Years,ALL,False,Northwestern University,OTHER,0,0,
NCT02362464,Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139,A Pilot Study of Long Term TARP Vaccination Using A Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccine in Previously Vaccinated Men on NCI 09-C-0139.,COMPLETED,2015-05-12,2022-03-25,2024-12-10,INTERVENTIONAL,PHASE2,14.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostatic Neoplasms|Neoplasms of Prostate|Prostate Cancer|Cancer Of Prostate|Stage D0 Prostate Cancer,Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine,BIOLOGICAL,1,4,18 Years,,MALE,False,National Cancer Institute (NCI),NIH,0,1,United States
NCT05263999,A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR),"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination With Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease",TERMINATED,2022-04-29,2025-05-12,2025-06-17,INTERVENTIONAL,PHASE3,158.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Graft Versus Host Disease|GVHD|Acute-graft-versus-host Disease|Acute GVHD|aGVHD,Itolizumab|EQ001 Placebo,DRUG|BIOLOGICAL,1,2,12 Years,,ALL,False,Equillium,INDUSTRY,1,118,Canada|United States|Australia|Belgium|Italy|Spain|South Korea|France|Portugal|Germany|Israel|New Zealand
NCT04346199,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19",COMPLETED,2020-06-12,2020-11-17,2021-09-17,INTERVENTIONAL,PHASE2,177.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,COVID-19,Acalabrutinib,DRUG,1,18,18 Years,130 Years,ALL,False,AstraZeneca,INDUSTRY,1,50,Japan|Italy|Argentina|France|Russia|Poland|Germany|South Africa|Peru|Turkey (Türkiye)|Chile|Mexico|India|Brazil
NCT03100032,Safety and Preliminary Effectiveness of NVD-001 for the Treatment of Low Grade Degenerative Lumbar Spondylolisthesis,"A Prospective Multi-centre, Randomised, Controlled Study to Evaluate the Safety and Preliminary Effectiveness of NVD-001 for the Treatment of Low Grade Degenerative Lumbar Spondylolisthesis by Interbody Fusion (L1 - S1)",COMPLETED,2017-01,2021-06,2021-08-13,INTERVENTIONAL,PHASE1|PHASE2,48.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Spondylolisthesis,NVD-001|Standard of Care,PROCEDURE|BIOLOGICAL,8,8,18 Years,,ALL,False,Novadip Biosciences,INDUSTRY,0,12,Czechia|Poland|Belgium
NCT03172598,"Study to Assess the Efficacy, Safety and Tolerability of MT- 8554 in Subjects With Painful Diabetic Peripheral Neuropathy","A Phase IIa, Multi-Centre, Randomised, Double-Blind, Cross-Over, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of MT-8554 in Subjects With Painful Diabetic Peripheral Neuropathy Incorporating an Open Label Pilot Arm",COMPLETED,2017-07-25,2018-08-08,2025-12-22,INTERVENTIONAL,PHASE2,61.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Painful Diabetic Peripheral Neuropathy,MT-8554 low dose|MT-8554 middle dose|MT-8554 high dose|Placebo,DRUG,2,2,18 Years,,ALL,False,Tanabe Pharma Corporation,INDUSTRY,0,3,Poland|Germany|Hungary
NCT02740387,Open Label Study of OTO-104 in Subjects With Meniere's Disease,"A 1-Year, Phase 2, Open-Label Safety Study of OTO-104 Given at 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease",TERMINATED,2016-06,2017-09,2017-09-15,INTERVENTIONAL,PHASE2,34.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Meniere's Disease,OTO-104,DRUG,1,3,18 Years,80 Years,ALL,False,"Otonomy, Inc.",INDUSTRY,0,1,Canada
NCT01952314,Medical Expulsive Therapy for Ureter Stone Using Naftopidil,"Medical Expulsive Therapy for Ureter Stone Using Naftopidil: Multicenter, Randomized, Double-blind, Placebo Controlled Study",COMPLETED,2014-05,2015-08,2015-12-10,INTERVENTIONAL,PHASE3,150.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Ureter Stones,Naftopidil 75mg|Placebo for Naftopidil|Standard treatment,DRUG,1,4,20 Years,,ALL,False,Seoul National University Hospital,OTHER,1,6,South Korea
NCT01767116,A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection,"A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)",COMPLETED,2012-12,2014-08,2021-07-12,INTERVENTIONAL,PHASE3,419.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Chronic Hepatitis C Infection,"ABT-450/r/ABT-267, ABT-333|Ribavirin|Placebo for ribavirin",DRUG,1,5,18 Years,70 Years,ALL,False,"AbbVie (prior sponsor, Abbott)",INDUSTRY,0,0,
NCT02976116,A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer,"Fruquintinib in Combination With Gefitinib as First-line Therapy in Patients With Advanced Non-squamous Non-small-cell Lung Cancer Harboring Activating EGFR Mutations : a Single-arm, Multicenter, Phase II Study",COMPLETED,2016-12,2019-06-28,2019-11-15,INTERVENTIONAL,PHASE2,50.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,NSCLC,Fruquintinib|Gefitinib,DRUG,2,4,18 Years,,ALL,False,Hutchison Medipharma Limited,INDUSTRY,0,2,China
NCT02678533,Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and Plerixafor,Pilot Study Assessing the Feasibility of CD34+ Cells Mobilization and Collection After Treatment With G-CSF and Plerixafor in Patients With Fanconi Anemia for Subsequent Treatment by Gene Therapy,COMPLETED,2017-02-10,2019-05-03,2025-09-11,INTERVENTIONAL,PHASE1|PHASE2,4.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Fanconi Anemia,G-CSF|Plerixafor,DRUG,1,1,2 Years,17 Years,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,2,1,France
NCT04633447,A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis,"A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis",TERMINATED,2020-12-10,2024-05-22,2025-07-01,INTERVENTIONAL,PHASE2,53.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Giant Cell Arteritis,Guselkumab|Placebo,DRUG,1,14,50 Years,,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,0,30,Canada|United States|Italy|Belgium|Spain|France|Poland|Germany|Israel
NCT01230138,Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis,"A Randomised, Double Blind, Placebo Controlled Efficacy and Safety Trial of Different Doses/Dose Regimens of FP187 Compared to Placebo in Moderate to Severe Plaque Psoriasis (Pivotal Registration Study)",COMPLETED,2010-09,2012-05,2012-12-11,INTERVENTIONAL,PHASE2,252.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Plaque Psoriasis,Placebo|FP187|FP187|FP187|FP187,DRUG,1,9,18 Years,90 Years,ALL,False,Forward-Pharma GmbH,INDUSTRY,0,2,Germany
NCT01716377,Healing With Venlafaxine After Injury (HELP),Healing With Venlafaxine After Injury: A Randomized Clinical Trial of Venlafaxine Following Motor Vehicle Collision,COMPLETED,2012-10,2016-09,2017-04-13,INTERVENTIONAL,PHASE2,20.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Neck Pain,Venlafaxine,DRUG,1,1,18 Years,50 Years,ALL,False,Rhode Island Hospital,OTHER,4,3,United States
NCT03189745,A Study To Evaluate A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered).,"A PHASE IIIB, OPEN STUDY TO EVALUATE THE IMMUNOGENICITY, REACTOGENICITY AND SAFETY OF A BOOSTER DOSE OF MENACWY-TT VACCINE ADMINISTERED 10 YEARS AFTER HEALTHY SUBJECTS AGED 11-17 YEARS RECEIVED EITHER MENACWY-TT VACCINE (NIMENRIX(REGISTERED)) OR MENCEVAX ACWY(REGISTERED).",COMPLETED,2017-08-01,2018-04-11,2020-10-12,INTERVENTIONAL,PHASE3,229.0,ACTUAL,,PARALLEL,PREVENTION,NONE,Meningococcal ACWY Disease,MenACWY-TT,BIOLOGICAL,1,8,20 Years,28 Years,ALL,True,Pfizer,INDUSTRY,0,1,Philippines
NCT01809977,Comparison of Partial Removal and Total Removal of the Corneal Epithelium on Keratoconus,Study of Surgical Methods for Keratoconus,COMPLETED,2012-07,2012-12,2013-03-13,INTERVENTIONAL,PHASE2,22.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Keratoconus,collagen cross-linking procedure (total removal)|collagen cross-linking procedure (partial removal),PROCEDURE,1,1,16 Years,40 Years,ALL,True,Isfahan University of Medical Sciences,OTHER,0,1,Iran
NCT02785172,Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis,"A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis",COMPLETED,2016-04,2017-01,2020-08-20,INTERVENTIONAL,PHASE2,154.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Psoriasis,IDP-118 Vehicle Lotion|IDP-118 Vehicle Cream|IDP-118 Lotion|Ultravate Cream,DRUG,1,0,18 Years,,ALL,True,"Bausch Health Americas, Inc.",INDUSTRY,0,14,United States
NCT01256372,An Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery,"An Explorative Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery",COMPLETED,2010-10,2011-08,2012-03-15,INTERVENTIONAL,PHASE2,77.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Cardiac Surgery|Coronary Artery Bypass|Aortic Aneurysm|Valve Surgery|Kidney Diseases,AP214|Placebo,DRUG,2,1,18 Years,,ALL,False,Action Pharma A/S,INDUSTRY,0,1,Denmark
NCT01213095,Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL),R-CVP Followed by Rituximab Maintenance Therapy for Patients With Advanced Marginal Zone B-cell Lymphoma,COMPLETED,2010-09,2015-09,2016-04-11,INTERVENTIONAL,PHASE2,48.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Lymphoma,rituximab,DRUG,1,2,20 Years,,ALL,False,Dong-A University Hospital,OTHER,0,1,South Korea
NCT03876795,Evaluation of Effectiveness of Combined Intra-articular and Intra-osseus Injection VS a Single Intra-articular Injection of Bone Marrow Concentrate,"Evaluation of Effectiveness of Combined Intra-articular and Intra-osseus Injection VS a Single Intra-articular Injection of Bone Marrow Concentrate for the Treatment of Osteoarthritis in the Knee. (INTERFACE) Double Blind, Randomized Clinical Trial",COMPLETED,2019-11-08,2023-03-01,2023-04-19,INTERVENTIONAL,PHASE3,86.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Osteoarthritis, Knee",Bone Marrow Concentrate,BIOLOGICAL,1,1,40 Years,70 Years,ALL,False,Istituto Ortopedico Rizzoli,OTHER,0,1,Italy
NCT06002295,A Comparative Analysis of 4% Chlorhexidine Versus Methylated Spirit as Prophylaxis of Omphalitis and Sepsis in Newborns,A Comparative Analysis of 4% Chlorhexidine Versus Methylated Spirit as Prophylaxis of Omphalitis and Sepsis in Newborns,COMPLETED,2020-09-12,2021-11-19,2023-08-23,INTERVENTIONAL,PHASE2,300.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Neonatal Sepsis|Omphalitis,Chlorhexidine Topical Cream|Methylated Spirit,DRUG,1,1,1 Day,10 Days,ALL,True,Sheikh Zayed Federal Postgraduate Medical Institute,OTHER,0,1,Pakistan
NCT02645175,Evaluate the Safety Profile and Ability of TW1025 Oral Solution to Decrease Fatigue,"A Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Safety Profile and Ability of TW1025 to Decrease Fatigue",TERMINATED,2016-01,2018-12,2016-10-21,INTERVENTIONAL,PHASE2,3.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Metastatic Breast Cancer|Fatigue,TW1025|Placebo,DIETARY_SUPPLEMENT,1,1,18 Years,80 Years,FEMALE,False,Meriyana Bio Inc.,INDUSTRY,1,0,
NCT02975557,Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD),"A Phase I/II Randomized, Placebo-Controlled, Double-Blind, Single-Center, Tolerability And Preliminary Efficacy Study Of Use of Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)",TERMINATED,2016-05,2017-04-13,2019-11-08,INTERVENTIONAL,PHASE1|PHASE2,15.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Dry Eye|Ocular Graft vs Host Disease|Meibomian Gland Dysfunction,Brimonidine 0.15%|Brimonidine 0.075%|Placebo,DRUG,1,0,18 Years,,ALL,False,"Sandeep Jain, MD",OTHER,1,2,United States
NCT02767557,Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients,"A Multinational, Randomized, Phase II Study of the Combination of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab, an IL-6R Inhibitor, as First-line Treatment in Patients With Locally Advanced or Metastatic Pancreatic Cancer.",COMPLETED,2017-01-26,2023-01-01,2023-09-22,INTERVENTIONAL,PHASE2,147.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Unresectable Pancreatic Carcinoma,Tocilizumab|Gemcitabine|nab-Paclitaxel,DRUG,1,8,18 Years,,ALL,False,Herlev Hospital,OTHER,1,2,Denmark|Norway
NCT03170401,Supplemental Enteral Protein in Critical Illness,Protein-enhanced Enteral Nutrition and Metabolomics in Critically Ill Trauma and Surgical Patients,COMPLETED,2016-11,2022-12,2024-06-05,INTERVENTIONAL,PHASE3,500.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Nutrition Disorder|Trauma|Critical Illness,Protein supplementation|Standard enteral nutrition,DIETARY_SUPPLEMENT|OTHER,1,2,18 Years,,ALL,False,University of Washington,OTHER,1,1,United States
NCT02485301,A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults,Safety and Immunogenicity Study of GSK Biologicals' Investigational Recombinant Chimpanzee Adenovirus Type 3-vectored Ebola Zaire Vaccine (GSK3390107A) in Adults in Africa,COMPLETED,2015-07-15,2016-12-23,2018-01-04,INTERVENTIONAL,PHASE2,3024.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Virus Diseases,GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)|Placebo,DRUG|BIOLOGICAL,21,2,18 Years,,ALL,True,GlaxoSmithKline,INDUSTRY,0,5,Mali|Senegal|Nigeria|Cameroon
NCT06414512,Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis,Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis,COMPLETED,2024-04-09,2024-10-02,2025-08-27,INTERVENTIONAL,PHASE2,48.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Cryptococcal Meningitis,AMBITION trial control|Flucytosine,DRUG,1,2,18 Years,,ALL,False,University of Minnesota,OTHER,3,2,Uganda
NCT04461119,"Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia","A Phase II, Randomized, 4-Week, Double-Blind, Placebo-Controlled, Multiple-Dose Study, Designed to Determine the Safety, Tolerability, EEG Effects and Preliminary Efficacy of Fixed Oral Doses of 7.5 and 15 MG BID of Evenamide in Patients With Chronic Schizophrenia Who Are Symptomatic on Their Current Second-Generation Antipsychotic Medication",COMPLETED,2020-06-16,2021-03-13,2021-05-20,INTERVENTIONAL,PHASE2,138.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Schizophrenia,Evenamide|Placebo,DRUG,2,6,18 Years,,ALL,False,Newron Pharmaceuticals SPA,INDUSTRY,0,14,United States|India
NCT02137330,Obalon in Children With Severe Obesity,Tolerance and Efficacy of the Swallowable Obalon® Gastric Balloons System in Children With Severe Obesity,COMPLETED,2014-01,2014-06,2015-07-22,INTERVENTIONAL,PHASE3,10.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Severe Pediatric Obesity (BMI > 97° pc -According to Centers for Disease Control and Prevention BMI Charts-)|Altered Liver Function Tests|Glycemic Intolerance,Swallowable Obalon® Gastric Balloon,DEVICE,1,1,9 Years,17 Years,ALL,False,Bambino Gesù Hospital and Research Institute,OTHER,0,1,Italy
